Targeted drug combo tested to control advanced breast cancer
NCT ID NCT04208178
Summary
This study tested whether adding the drug alpelisib to standard therapy helps control advanced HER2-positive breast cancer that has a specific genetic mutation (PIK3CA). It was a Phase 3 trial for patients whose cancer had not progressed after initial chemotherapy. The study was stopped early because the standard treatments for this cancer were changing, not due to safety concerns.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HER2+BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Highlands Oncology Group
Fayetteville, Arkansas, 72703, United States
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Liège, 4000, Belgium
-
Novartis Investigative Site
Changchun, Jilin, 130021, China
-
Novartis Investigative Site
Shanghai, 200032, China
-
Novartis Investigative Site
Saint-Cloud, Hauts De Seine, 92210, France
-
Novartis Investigative Site
Saint-Herblain, 44805, France
-
Novartis Investigative Site
Florence, FI, 50134, Italy
-
Novartis Investigative Site
Kuala Lumpur, 59100, Malaysia
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
University of California LA
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.